Impaired Myocardial Blood Flow Reserve in Subjects with Metabolic Syndrome Analyzed Using Positron Emission Tomography and N-13 Labeled Ammonia

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2009 Nov 17

PMID 19915835

Citations 6

Authors

Hiroki Teragawa

Koichi Morita

Hiroki Shishido

Nobuaki Otsuka

Yutaka Hirokawa

Kazuaki Chayama

Nagara Tamaki

Yasuki Kihara

Affiliations

Soon will be listed here.

Abstract

Purpose: Coronary vasomotor response might be impaired in metabolic syndrome (MS); however, the precise abnormality has not been elucidated. The aim of this study was to assess coronary-vasomotor response in MS subjects using N-13 labeled ammonia and positron emission tomography.

Methods And Results: Myocardial blood flow (MBF) was measured at rest and during adenosine infusion in MS subjects (n = 13, MS group) with no definite evidence of heart disease and in subjects without MS (n = 14, non-MS group). Coronary vascular resistance (CVR) was calculated by dividing the mean aortic blood pressure by MBF. Myocardial blood flow reserve (MFR) was calculated as the ratio of the MBF during adenosine infusion to that during rest. Blood chemical parameters were measured to evaluate their relationship with MFR. During adenosine infusion, MBF was lower (p = 0.0085) and CVR higher (p = 0.0128) in the MS group than in the non-MS group and MFR was significantly lower in the MS group than in the non-MS group (2.13 +/- 0.99 vs. 3.38 +/- 0.95, p = 0.0027). Multivariate analysis demonstrated that the homeostasis model assessment-insulin resistance (p < 0.05) and the presence of hypertension (p < 0.05) were independent determinants of MFR.

Conclusions: The results indicate that MFR was impaired in MS subjects, suggesting that an abnormal coronary microvascular response occurred in these subjects. This abnormality may have been partially due to insulin resistance and hypertension.

Citing Articles

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis.

Bilak J, Alam U, Miller C, McCann G, Arnold J, Kanagala P Card Fail Rev. 2022; 8:e24.

PMID: 35846985 PMC: 9274364. DOI: 10.15420/cfr.2022.12.

Comparison of Microcirculatory Perfusion in Obese and Non-Obese Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass.

Boly C, Venhuizen M, Dekker N, Vonk A, Boer C, van den Brom C J Clin Med. 2021; 10(3).

PMID: 33530543 PMC: 7865338. DOI: 10.3390/jcm10030469.

Cardiovascular consequences of metabolic syndrome.

Tune J, Goodwill A, Sassoon D, Mather K Transl Res. 2017; 183:57-70.

PMID: 28130064 PMC: 5393930. DOI: 10.1016/j.trsl.2017.01.001.

De Novo Glutamine Synthesis: Importance for the Proliferation of Glioma Cells and Potentials for Its Detection With 13N-Ammonia.

He Q, Shi X, Zhang L, Yi C, Zhang X, Zhang X Mol Imaging. 2016; 15.

PMID: 27118759 PMC: 5470141. DOI: 10.1177/1536012116645440.

Contribution of voltage-dependent K⁺ channels to metabolic control of coronary blood flow.

Berwick Z, Dick G, Moberly S, Kohr M, Sturek M, Tune J J Mol Cell Cardiol. 2011; 52(4):912-9.

PMID: 21771599 PMC: 3202075. DOI: 10.1016/j.yjmcc.2011.07.004.

References

Takeuchi H, Saitoh S, Takagi S, Ohnishi H, Ohhata J, Isobe T . Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men--the Tanno and Sobetsu Study. Hypertens Res. 2005; 28(3):203-8. DOI: 10.1291/hypres.28.203. View

Steinberg H, Chaker H, LEAMING R, Johnson A, Brechtel G, Baron A . Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996; 97(11):2601-10. PMC: 507347. DOI: 10.1172/JCI118709. View

Malik S, Wong N, Franklin S, Kamath T, LItalien G, Pio J . Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004; 110(10):1245-50. DOI: 10.1161/01.CIR.0000140677.20606.0E. View

Yoshizumi T, Nakamura T, Yamane M, Islam A, Menju M, Yamasaki K . Abdominal fat: standardized technique for measurement at CT. Radiology. 1999; 211(1):283-6. DOI: 10.1148/radiology.211.1.r99ap15283. View

Schindler T, Cardenas J, Prior J, Facta A, Kreissl M, Zhang X . Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol. 2006; 47(6):1188-95. DOI: 10.1016/j.jacc.2005.10.062. View

McNeill A, Rosamond W, Girman C, Golden S, Schmidt M, East H . The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005; 28(2):385-90. DOI: 10.2337/diacare.28.2.385. View

Quinones M, Hernandez-Pampaloni M, Schelbert H, Bulnes-Enriquez I, Jimenez X, Hernandez G . Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med. 2004; 140(9):700-8. DOI: 10.7326/0003-4819-140-9-200405040-00009. View

Kozakova M, Palombo C, Pratali L, Pittella G, Galetta F, LAbbate A . Mechanisms of coronary flow reserve impairment in human hypertension. An integrated approach by transthoracic and transesophageal echocardiography. Hypertension. 1997; 29(2):551-9. DOI: 10.1161/01.hyp.29.2.551. View

Solymoss B, Bourassa M, Campeau L, Sniderman A, Marcil M, LEsperance J . Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol. 2004; 93(2):159-64. DOI: 10.1016/j.amjcard.2003.09.032. View

10.

Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C . Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004; 43(10):1817-22. DOI: 10.1016/j.jacc.2003.12.049. View

11.

Moller D, Kaufman K . Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med. 2005; 56:45-62. DOI: 10.1146/annurev.med.56.082103.104751. View

12.

Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S . Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol. 2007; 50(12):1144-9. DOI: 10.1016/j.jacc.2007.06.013. View

13.

Herzog B, Husmann L, Valenta I, Gaemperli O, Siegrist P, Tay F . Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol. 2009; 54(2):150-6. DOI: 10.1016/j.jacc.2009.02.069. View

14.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

15.

Tsukamoto T, Morita K, Naya M, Katoh C, Inubushi M, Kuge Y . Myocardial flow reserve is influenced by both coronary artery stenosis severity and coronary risk factors in patients with suspected coronary artery disease. Eur J Nucl Med Mol Imaging. 2006; 33(10):1150-6. DOI: 10.1007/s00259-006-0082-x. View

16.

Yokoyama I, Ohtake T, Momomura S, Yonekura K, Nishikawa J, Sasaki Y . Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes. 1998; 47(1):119-24. DOI: 10.2337/diab.47.1.119. View

17.

Schindler T, Zhang X, Vincenti G, Mhiri L, Lerch R, Schelbert H . Role of PET in the evaluation and understanding of coronary physiology. J Nucl Cardiol. 2007; 14(4):589-603. PMC: 1995749. DOI: 10.1016/j.nuclcard.2007.05.006. View

18.

Gami A, Witt B, Howard D, Erwin P, Gami L, Somers V . Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007; 49(4):403-14. DOI: 10.1016/j.jacc.2006.09.032. View

19.

Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K . Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004; 164(10):1066-76. DOI: 10.1001/archinte.164.10.1066. View

20.

Namdar M, Koepfli P, Grathwohl R, Siegrist P, Klainguti M, Schepis T . Caffeine decreases exercise-induced myocardial flow reserve. J Am Coll Cardiol. 2006; 47(2):405-10. DOI: 10.1016/j.jacc.2005.08.064. View